Front. Med.Frontiers in MedicineFront. Med.2296-858XFrontiers Media S.A.10.3389/fmed.2026.1739128Systematic ReviewThe effectiveness of Traditional Chinese Medicine in treating cancer related anemia: a systematic review and meta-analysisLiQuan-yao1†MethodologyConceptualizationInvestigationWriting – original draftZhangZi-yu2†InvestigationConceptualizationMethodologyWriting – original draftYangWen-xiao2SoftwareData curationWriting – original draftFormal analysisLiuHui1Formal analysisData curationSoftwareWriting – original draftLiXi1VisualizationSoftwareWriting – original draftMethodologyQiuWen-chao1SoftwareMethodologyWriting – original draftVisualizationGuoZhao-wei1Writing – original draftSoftwareVisualizationMethodologyShiJun1*ResourcesValidationProject administrationWriting – review & editingFunding acquisitionSupervisionConceptualizationShanghai Fourth People’s Hospital Affiliated to Tongji University, Shanghai, ChinaYueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaCorrespondence: Jun Shi, shijundoctor@163.com
The aim is to systematically evaluate the clinical efficacy of Traditional Chinese Medicine (TCM) in the treatment of cancer related anemia (CRA), and to provide higher quality evidence-based medical evidence for the treatment of CRA with TCM.
Methods
Pubmed, Embase, Cochrane library, Scopus, Web of Science, China National Knowledge Infrastructure (CNKI), China Biology Medicine Disk (CBM) and WanFang were searched for the literature on TCM treatment of CRA included in the databases from the establishment of the databases to December 2025. Meta-analysis was performed using ReVman5.3 software.
Results
6,201 relevant literatures were retrieved. According to inclusion and exclusion criteria, a total of 58 literatures were included, with a total of 4,308 patients, including 2,157 patients in the treatment group and 2,151 patients in the control group. The treatment group was better than the control group in improving hemoglobin level, clinical efficacy, KPS score, TCM syndrome efficacy, TCM Syndrome Score, immune function and red blood cell count, the difference was statistically significant (P < 0.05). By drawing a funnel figure of hemoglobin levels, it was found that the left and right sides of the funnel figure were basically symmetrical, indicating that the publication bias of this study was low. It can be considered that TCM treatment can significantly improve hemoglobin and improve the anemia of patients.
Conclusion
Traditional Chinese Medicine can significantly improve CRA, enhance TCM syndrome and immune function, and improve patients’ quality of life.
cancer related anemiaChinese herbalhemoglobinmeta-analysisquality of lifeThe author(s) declared that financial support was received for this work and/or its publication. This work was supported by Special Scientific Research Project of Shanghai Fourth People’s Hospital (sykyqd10201).section-at-acceptanceHematologyIntroduction
Cancer related anemia (CRA) is a common complication occurring during the development and treatment of tumors (1). Its primary manifestations include fatigue, pallor, and dizziness. CRA has a high occurrence rate, studies have shown that the incidence of CRA in China reaches 49.24%, and the incidence rises to as high as 90% after chemotherapy. However, the treatment rate remains low, with up to 92.84% of CRA patients receiving no anemia-correcting therapy (2), leading to aggravated anemia symptoms and severely compromised quality of life. Relevant studies indicate that cancer patients with anemia have a 65% increased overall risk of mortality compared to those without anemia (1). CRA is generally induced by multiple factors, including cancer-related factors, and antitumor treatments. Current evidence tends to implicate inflammation, malnutrition, renal impairment, abnormal iron metabolism, and bone marrow hematopoietic dysfunction, among others (3). The main modern medical treatments for CRA include blood transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation. Although blood transfusion can rapidly correct blood loss, it carries risks of complications such as infection, hemolysis, and thrombosis (4). According to the 2022 guidelines of the Chinese Society of Clinical Oncology (3), erythropoietin (EPO) therapy has certain limitations and is not recommended, and it exhibits a delayed onset of action, and is effective in only a subset of patients. Iron supplements are only about 10% absorbed by the human body and are often associated with severe gastrointestinal irritation. Traditional Chinese Medicine (TCM) has a long history in the treatment of CRA and offers unique advantages with a favorable safety profile. Therefore, it is of great significance to actively investigate the therapeutic role of TCM in CRA. Although preliminary studies (5, 6) have explored the role of TCM in the treatment of CRA, limitations such as earlier search timeframes, limited database coverage, and insufficient assessment of evidence quality remain. Therefore, this study further updates the search period, incorporates databases including Embase, Scopus, and Web of Science, strictly adheres to the PRISMA guidelines, applies the GRADE approach to grade the quality of evidence, and systematically evaluates the clinical efficacy of oral Chinese herbal medicine in treating CRA. The aim of this study is to provide higher-quality evidence-based support for TCM in the treatment of CRA through a more comprehensive, rigorous, and updated evidence synthesis.
Research methods
The study was conducted in strict compliance with the PRISMA guidelines for systematic reviews and meta-analyses.
Literature search
The literature search strategy was developed in accordance with the Cochrane Systematic Reviews Handbook guidelines. The following databases were searched from their inception to December 2025 for relevant clinical studies on the treatment of CRA with TCM, such as PubMed, Embase, Cochrane Library, Scopus, Web of Science, China National Knowledge Infrastructure (CNKI), China Biology Medicine Disk (CBM), and WanFang. The search terms included “Cancer related anemia,” “Tumor related anemia,” “Anemia,” “Traditional Chinese Medicine,” “Chinese herbal,” “Herbal medicine,” “TCM,” “Randomized” and “RCT.” And the search strategy was adjusted according to different databases. The search strategy takes pubmed as an example: ((((Cancer related anemia) OR (Tumor related anemia)) OR (Anemia)) AND ((((Traditional Chinese Medicine) OR (Chinese herbal)) OR (Herbal medicine)) OR (TCM))) AND ((Randomized[Title/Abstract]) OR (RCT[Title/Abstract])). In addition, we manually searched for relevant studies to obtain as much information as possible. The manual search method is as follows: (1) scanning the reference lists of all included articles and relevant systematic reviews. (2) Searching the trial registries ClinicalTrials.gov, Chinese Clinical Trial Registry, and the International Traditional Medicine Clinical Trial Registry. (3) Reviewing the tables of contents of key Chinese medicine journals (e.g., Zhongguo Za Zhi, Zhongguo Zhong Yao Za Zhi) from the past 10 years.
Inclusion criteria
(1) Design: randomized controlled trials (RCTs).
(2) Participant: patients with a histologically or cytologically confirmed diagnosis of malignant tumors who also met the diagnostic criteria for anemia.
(3) Interventions: the control group received conventional or symptomatic treatment (e.g., iron supplements, folic acid, EPO, etc.). The treatment group received oral Chinese herbal medicine (either proprietary Chinese medicine or decoction), either as a standalone intervention or in addition to the control group’s regimen.
(4) Outcomes: Primary Outcome: Hemoglobin level (g/L). Secondary Outcomes: Clinical efficacy, Red blood cell count, Karnofsky Performance Status (KPS) score, TCM syndrome score, TCM syndrome efficacy, and immune function indicators (CD3+, CD4+, CD8+, CD4+/CD8+).
(5) Publication: full-text articles published in peer-reviewed journals.
Exclusion criteria
(1) Conference literature.
(2) Literature from which valid data could not be extracted.
(3) Duplicate publications.
Data extraction
Two researchers independently screened the literature according to the inclusion and exclusion criteria. Initial screening was performed based on the title, abstract, and keywords, followed by a full-text review for secondary screening. The screening results were cross-checked by both researchers. Any discrepancies were resolved through consultation with a third researcher holding a senior professional title. The primary extracted information including author(s), year of publication, group size, randomization method, interventions, and outcome measures.
Quality assessment criteria
The Cochrane-recommended risk of bias assessment tool, RoB 2.0, was used to evaluate the quality of the included literature. This assessment covered the following domains: randomization process, deviations from intended interventions, definite outcome indicator, outcome measurement, and selection of the reported result. Two researchers independently performed the risk assessment. Any discrepancies were resolved through consultation with a third researcher.
Statistical analysis
Meta-analysis of the included literature was performed using RevMan software (version 5.3). Firstly, a heterogeneity testing was conducted for each study. If no statistical significance was observed (P > 0.05, I2 < 50%), the included studies were considered to lack heterogeneity, and a fixed-effects model was applied for analysis. Conversely, if statistical significance was present (P < 0.05, I2 > 50%), heterogeneity among the included studies was indicated, necessitating further investigation into its sources to determine the suitability of a random-effects model for analysis. For dichotomous data, the odds ratio (OR) with a 95% confidence interval (CI) was used as the statistical measure for efficacy analysis. For continuous data, the mean difference (MD) with a 95% CI was employed as the statistical measure for efficacy analysis.
ResultsLiterature search results
This study identified 6,201 relevant articles through literature search. After removing 2,786 duplicate records using Note Express software. Subsequent screening of remaining articles through title and abstract analysis removed 3,291 articles. The full texts of the remaining 124 articles were thoroughly reviewed. Finally, according to the inclusion and exclusion criteria, 58 articles were included in the study. See Figure 1.
Flow chart of literature search.
A PRISMA flow diagram outlining study selection for data mining. Six thousand two hundred one records were identified, two thousand seven hundred eighty-six remained after duplicates, three thousand four hundred fifteen were screened, one hundred twenty-four full texts were assessed for eligibility, and fifty-eight studies were included. Reasons for exclusion at each stage are listed in adjacent boxes.Basic characteristics and quality assessment of included literature
A total of 58 randomized controlled trials were included in this study, involving 4,308 patients with CRA. Among these patients, 2,157 were assigned to the treatment group and 2,151 to the control group. The baseline characteristics, such as age and gender, were consistent across the included studies, indicating comparability among the study groups. See Table 1.
Basic characteristics of the included literature.
Included literature
Sample size
Grouping
Baseline
Intervention
Outcome measures
Control group
Treatment group
Control group
Treatment group
Bai (36)
44
44
Simple randomization
Coincide
EPO
EPO+TCM
➀➁➂➃
Cao et al. (38)
30
30
Randomization
Coincide
EPO
EPO+TCM
➀➁➂➃➄➆➉
Chen (35)
30
30
Randomization
Coincide
Symptomatic treatment
Standard chemotherapy+TCM
➀➁➂➆➇➈➉
Chen et al. (39)
44
44
Randomization
Coincide
Conventional treatment
Conventional treatment+TCM
➀➁➂➃➄➇➈➉
Cheng et al. (66)
32
33
Lottery method
Coincide
EPO
EPO+TCM
➀➁➂
Cong (7)
40
40
Random number table
Coincide
Conventional treatment
Conventional treatment+TCM
➀➁➂
Feng et al. (8)
64
64
Random number table
Coincide
Symptomatic treatment
Symptomatic treatment+TCM
➀➁➂➄
Fu et al. (9)
28
32
Random number table
Coincide
Conventional treatment
TCM
➀➁➂➃➄➇➈➉
He et al. (10)
40
40
Random number table
Coincide
Conventional treatment
Conventional treatment+TCM
➀➁➂
Hu and Jiang (40)
32
34
Randomization
Coincide
Donkey-hide gelatin granules
TCM
➀➁➂➅➆➇➈➉
Hu and Liao (33)
30
30
Envelope method
Coincide
EPO
EPO+TCM
➀➁➂➃➅
Huang (41)
22
23
Randomization
Coincide
Shengxue Ning+EPO
Shengxue Ning+EPO+TCM
➀➁
Huang et al. (11)
30
30
Random number table
Coincide
Conventional treatment
TCM
➀➂➆➇➈➉
Huang et al. (42)
30
30
Randomization
Coincide
Xiangsha LiuJun BuGuZhi Decoction combined with SiWu Decoction
Xiangsha LiuJun BuGuZhi Decoction combined with SiWu Decoction+TCM
Among the 58 included clinical studies, 27 studies (7–32) employed random number table for group allocation, 2 studies (33, 34) employed the envelope method, 2 studies (11, 35) used a lottery method, and 2 studies (36, 37) applied simple randomization. The remaining 25 studies (9, 35, 38–62) only mentioned randomization without specifying the method. Additionally, allocation concealment was inadequate in 2 studies (36, 56). Blinding was not mentioned in any of the studies. All studies reported complete outcome data with no selective reporting. See Figures 2, 3.
Risk-of-bias graph.
Horizontal bar graph displaying risk of bias across six study domains: Overall Bias, Selection of the reported result, and Measurement of the outcome indicate predominantly low risk; Deviations from intended interventions and one other category reveal some concerns, while Overall Bias and Randomization process show small portions assessed as high risk. Legend denotes green for low risk, yellow for some concerns, and red for high risk.
Risk-of-bias summary.
Vertical risk of bias summary table showing studies listed in rows and domains listed in columns: randomization process, deviation from intended intervention, missing outcome data, measurement of the outcome, selection of the reported result, and overall. Green circles with plus symbols indicate low risk, yellow circles with question marks indicate unclear risk, and red circles with minus symbols indicate high risk. The majority of studies show low risk across all domains, with a few exceptions showing unclear or high risk in certain domains and in overall assessment.Meta-analysis resultsPrimary outcome measureAnalysis of hemoglobin
A total of 58 studies involving 4,308 patients were included. The heterogeneity testing indicated significant heterogeneity among the 58 studies (P < 0.05, I2 = 96%), and thus a random-effects model was applied. The meta-analysis demonstrated a statistically significant difference in hemoglobin levels between the two groups (MD = 11.52, 95% CI [9.21, 13.84], P < 0.05). See Figure 4.
Hemoglobin analysis.
Forest plot displaying a meta-analysis of multiple studies comparing experimental and control groups, showing mean differences with confidence intervals for each study, overall pooled effect size, and statistical measures of heterogeneity and significance at the bottom.Publication bias
A funnel plot was constructed for the primary outcome measure. The results demonstrated that the funnel plot was largely symmetrical on both sides, indicating a low likelihood of publication bias in this study. It can be concluded that TCM significantly increases hemoglobin levels and improves anemia in patients. See Figure 5.
Funnel diagram of hemoglobin analysis.
Funnel plot showing open circles representing study points plotted along axes labeled SE(MD) for the y-axis and MD for the x-axis, with two blue dashed lines forming an inverted funnel.Subgroup analysis
A subgroup analysis of hemoglobin levels was performed, with subgroups stratified based on whether conventional treatment involved EPO. The interventions were divided into two subgroups: conventional treatment (excluding EPO) combined with TCM and conventional treatment (including EPO) combined with TCM. The subgroup analysis revealed that the overall results remained consistent regardless of whether EPO was included in the conventional treatment. TCM was identified as the core component of the intervention, suggesting that the study findings are robust. See Figure 6.
Subgroup analysis of hemoglobin.
Forest plot summarizing meta-analysis of multiple studies comparing conventional treatment with or without EPO plus TCM versus control for a quantitative outcome, showing individual study means, confidence intervals, subgroup and overall weighted mean differences, and test statistics.Secondary outcome measuresAnalysis of clinical efficacy
A total of 49 studies involving 3,600 patients were included. The heterogeneity testing indicated homogeneity among the 49 studies (P > 0.05, I2 = 0%), and thus a fixed-effects model was applied. The meta-analysis demonstrated a statistically significant difference in clinical efficacy between the two groups (OR = 4.46, 95% CI [3.73, 5.33], P < 0.05). See Figure 7.
Clinical effect analysis.
Forest plot summarizing 48 studies comparing experimental and control groups, showing odds ratios and confidence intervals mainly favoring the experimental group, with an overall combined odds ratio of 4.46 and minimal heterogeneity.Analysis of red blood cell count
A total of 46 studies involving 3,611 patients were included. The heterogeneity testing indicated significant heterogeneity among the 46 studies (P < 0.05, I2 = 94%), and thus a random-effects model was applied. The meta-analysis demonstrated a statistically significant difference in red blood cell count between the two groups (MD = 0.48, 95% CI [0.36, 0.60], P < 0.05). See Figure 8.
Red blood cell count analysis.
Forest plot displaying meta-analysis results of 46 studies comparing experimental and control groups, with mean differences and ninety-five percent confidence intervals consistently favoring the experimental group; pooled effect size is 0.48, confidence interval 0.36 to 0.60, and heterogeneity I squared is ninety-four percent.Analysis of KPS scores
A total of 22 studies involving 1,551 patients were included. The heterogeneity testing indicated significant heterogeneity among the 22 studies (P < 0.05, I2 = 82%), and thus a random-effects model was applied. The meta-analysis demonstrated a statistically significant difference in KPS scores between the two groups (MD = 7.49, 95% CI [6.21, 8.77], P < 0.05). See Figure 9.
Karnofsky Performance Status (KPS) scores analysis.
Forest plot summarizes meta-analysis results comparing experimental and control groups across 20 studies, displaying mean difference with ninety-five percent confidence intervals. Most studies favor the experimental group. Pooled mean difference is seven point four nine, confidence interval six point two one to eight point seven seven. Heterogeneity is high at eighty-two percent.Analysis of TCM syndrome score
A total of 23 studies involving 1,724 patients were included. The heterogeneity testing indicated significant heterogeneity among the 23 studies (P < 0.05, I2 = 97%), and thus a random-effects model was applied. The meta-analysis demonstrated a statistically significant difference in TCM syndrome scores between the two groups (MD = −2.36, 95% CI [−3.73, −1.00], P < 0.05). See Figure 10.
Traditional Chinese Medicine (TCM) syndrome scores analysis.
Forest plot showing a meta-analysis of twenty-three studies comparing experimental and control groups. Each study is represented by a horizontal line with a square for mean difference and confidence interval. The overall effect estimate is displayed as a diamond at the bottom, indicating a combined mean difference of negative two point three six with a ninety-five percent confidence interval from negative three point seven three to negative one point zero zero. The x-axis shows the direction of effect, while heterogeneity is high with an I-squared value of ninety-seven percent.Analysis of TCM syndrome efficacy
A total of 14 studies involving 992 patients were included. The heterogeneity testing indicated homogeneity among the 10 studies (P > 0.05, I2 = 0%), and thus a fixed-effects model was applied. The meta-analysis demonstrated a statistically significant difference in TCM syndrome efficacy between the two groups (OR = 4.61, 95% CI [3.44, 6.16], P < 0.05). See Figure 11.
Curative effect analysis of TCM syndromes.
Forest plot summarizing results of 14 studies comparing experimental and control groups, showing odds ratios with 95 percent confidence intervals for each study. All but one confidence interval favor the experimental group, with the overall pooled odds ratio of 4.61 [3.44, 6.16], indicating statistical significance. Heterogeneity is low at I squared equals 25 percent.Immune function analysis
Analysis of CD3+ cells included 14 studies involving 1,060 patients. The heterogeneity testing indicated significant heterogeneity among the 14 studies (P < 0.05, I2 = 83%), and thus a random-effects model was applied. The meta-analysis demonstrated a statistically significant difference in CD3+ levels between the two groups (MD = 5.53, 95% CI [3.77, 7.28], P < 0.05). See Figure 12A. Analysis of CD4+ cells included 14 studies involving 1,098 patients. The heterogeneity testing indicated significant heterogeneity among the 14 studies (P < 0.05, I2 = 77%), and thus a random-effects model was applied. The meta-analysis demonstrated a statistically significant difference in CD4+ levels between the two groups (MD = 5.39, 95% CI [4.29, 6.50], P < 0.05). See Figure 12B. Analysis of CD8+ cells included 14 studies involving 1,098 patients. The heterogeneity testing indicated significant heterogeneity among the 14 studies (P < 0.05, I2 = 86%), and thus a random-effects model was employed. The meta-analysis demonstrated a statistically significant difference in CD8+ levels between the two groups (MD = −1.49, 95% CI [−2.40, −0.58], P < 0.05). See Figure 12C. Analysis of the CD4+/CD8+ included 16 studies involving 1,258 patients. The heterogeneity testing indicated significant heterogeneity among the 16 studies (P < 0.05, I2 = 89%), and thus a random-effects model was applied. The meta-analysis demonstrated a statistically significant difference in the CD4+/CD8+ between the two groups (MD = 0.30, 95% CI [0.22, 0.38], P < 0.05). See Figure 12D.
Four forest plots labeled A, B, C, and D display meta-analysis results comparing experimental and control means across multiple studies, with mean values, standard deviations, sample sizes, weight percentages, mean differences, and confidence intervals for each study, alongside aggregated summary statistics for each panel.Grading evidence
A total of 10 outcome indicators were systematically evaluated in this study. None of the included studies involved allocation concealment or blinding, which was rated as a serious risk of bias. The literature included for the Hemoglobin and TCM syndrome efficacy outcomes demonstrated homogeneity, therefore, the inconsistency of the remaining outcome indicators was rated as serious. All outcome indicators were considered direct evidence, with no indirectness present. The data from the literature included in this study were complete, with no selective reporting identified. See Table 2.
Grading evidence of the included literature.
Outcome measures
Included literature
Bias risk
Inconsistency
Indirect
Uncertainty
Publication bias
Group
Statistical measure (95% CI)
Grading
Control group
Treatment group
Hemoglobin
58
Serious
No
No
No
No
2157
2151
MD = 11.52, 95% CI [9.21, 13.84]
Middle
Clinical efficacy
49
Serious
Serious
No
No
No
1806
1794
OR = 4.46, 95% CI [3.73, 5.33]
Low
Red blood cell count
46
Serious
Serious
No
No
No
1809
1802
MD = 0.48, 95% CI [0.36, 0.60]
Low
KPS score
22
Serious
Serious
No
No
No
781
770
MD = 7.49, 95% CI [6.21, 8.77]
Low
TCM syndrome score
23
Serious
Serious
No
No
No
865
859
MD = −2.36, 95% CI [−3.73, −1.00]
Low
TCM syndrome efficacy
14
Serious
No
No
No
No
498
494
OR = 4.61, 95% CI [3.44, 6.16]
Middle
CD3+
14
Serious
Serious
No
No
No
533
527
MD = 5.53, 95% CI [3.77, 7.28]
Low
CD4+
14
Serious
Serious
No
No
No
552
546
MD = 5.39, 95% CI [4.29, 6.50]
Low
CD8+
14
Serious
Serious
No
No
No
552
546
MD = −1.49, 95% CI [−2.40, −0.58]
Low
CD4+/CD8+
16
Serious
Serious
No
No
No
632
626
MD = 0.30, 95% CI [0.22, 0.38]
Low
Allocation concealment and blinding are not involved (downgraded by one level). Heterogeneity exists in the included literature (downgraded by one level).
Discussion
Traditional Chinese Medicine has a long history in the treatment of anemia and possesses unique advantages. CRA falls within the categories of “blood depletion” and “consumptive disease” in TCM, primarily characterized by deficiency of qi and blood. Its disease location is in the spleen and kidney, and it is closely related to the liver. According to TCM theory, in patients with malignant tumors, prolonged illness leads to visceral deficiency, or radiotherapy and chemotherapy consume healthy qi, resulting in dysfunction of the spleen and stomach in transportation and transformation, which consequently leads to insufficient generation and transformation of qi and blood. Additionally, patients often present with qi stagnation, blood stasis, phlegm coagulation, dampness accumulation, and heat toxin, which affect the liver’s function of storing blood, leading to a reduction in blood volume. The kidney stores essence, prolonged illness damages the kidney, leading to kidney essence deficiency and liver blood depletion, which consumes blood and injures essence. Under the combined action of “cancer” and “toxin,” the key pathogenesis characterized primarily by “deficiency” accompanied by “toxin and stasis” is formed (63). Therefore, the treatment principle should focus on tonifying deficiency, combined with resolving toxin and removing stasis.
A total of 48 studies on TCM for the treatment of CRA were included in this analysis. The results demonstrated that the combination of TCM with conventional treatment or the use of TCM alone significantly increased hemoglobin (MD = 11.52, 95% CI [9.21, 13.84], P < 0.05) and improved clinical efficacy (OR = 4.46, 95% CI [3.73, 5.33], P < 0.05) in patients with CRA compared to conventional treatment alone. Improvements were also observed in red blood cell count, KPS score, TCM syndrome score, and TCM syndrome efficacy. Furthermore, TCM treatment exhibited a positive immunomodulatory effect, as indicated by increased proportions of CD3+ and CD4+ T cells and an elevated CD4+/CD8+. Funnel plot analysis of hemoglobin showed approximate symmetry, suggesting a low risk of publication bias and supporting the reliability of the study conclusions. These findings indicate that TCM may provide an effective adjunctive strategy for the comprehensive management of CRA. In addition, some of the included studies compared the safety profiles of TCM and conventional treatment. Overall, conventional treatment for CRA was associated with adverse reactions such as dizziness, headache, abdominal pain, bloating, nausea, vomiting, skin allergies, and even abnormal liver function. In contrast, TCM treatment for CRA not only enhanced clinical efficacy but also resulted in a significantly lower incidence of adverse reactions compared to conventional treatment.
From a modern medical perspective, TCM ameliorates CRA through multi-target mechanisms. The study found that TCM can improve immune function indicators, which is related to its ability to modulate the immunosuppressive state within the tumor microenvironment and mitigate inflammatory responses. Inflammatory responses can lead to anemia by regulating hepcidin, thereby inhibiting iron absorption and release and causing iron metabolism disorders (64). Many TCM herbs for replenishing Qi and nourishing blood possess anti-inflammatory properties, stimulate bone marrow hematopoiesis, and enhance immune function. This aligns with the TCM theory of “fortifying the spleen and tonifying the kidney, replenishing Qi and nourishing blood” for improving CRA and provides further evidential support for the clinical efficacy observations in this study.
The findings of this study are consistent with earlier meta-analyses by Huang et al. (5) and Dang et al. (6), all supporting the positive efficacy of TCM for CRA. However, the study significantly extends and deepens previous meta-analyses in several key aspects. First, the literature search was updated to 2025 and covered multiple international databases, incorporating high-quality clinical studies published in recent years, thereby enhancing the timeliness and comprehensiveness of the evidence. Second, this study strictly adhered to the PRISMA guidelines and, for the first time in a systematic review on this topic, applied the Cochrane RoB 2.0 tool and the GRADE approach to standardize the assessment of evidence quality, making the conclusions of this study more objective and standardized.
Limitations
There are some limitations in the application of TCM for CRA. Firstly, the protocol for this systematic review was not prospectively registered, and the number of cases in the literature included in this study was relatively small, and large-sample clinical studies are lacking. Moreover, there is no standardized protocol for treatment duration and observation periods in clinical study. Secondly, variations in participant characteristics across the included studies resulted in significant clinical heterogeneity, which may affect the assessment of therapeutic efficacy. Finally, most studies had a relatively high risk of bias, and two studies included in this study did not adequately implement blinding, which may introduce selection bias, performance bias, and measurement bias (65). Therefore, future large-sample, multicenter, prospective studies are warranted to evaluate the clinical efficacy of TCM in treating CRA, with the aim of providing higher-quality medical evidence.
Conclusion
In summary, current clinical evidence indicates that as an effective complementary therapy for CRA, TCM can safely and effectively improve hemoglobin, immune function, clinical symptoms, and quality of life in patients with CRA. In clinical practice, for CRA patients who respond poorly to conventional treatments or cannot tolerate its side effects, considering the combined use of TCM under the guidance of TCM syndrome differentiation by a qualified TCM practitioner represents a reasonable therapeutic option. However, given the overall low certainty of the current evidence, it is presently insufficient to formulate a strong recommendation for the routine inclusion of TCM in CRA treatment guidelines. The primary value of this study lies in systematically reviewing the existing evidence, clarifying its strengths and limitations, and providing direction for future pivotal research aimed at generating higher-level evidence.
Data availability statement
The original contributions presented in this study are included in this article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
Q-yL: Methodology, Conceptualization, Investigation, Writing – original draft. Z-yZ: Investigation, Conceptualization, Methodology, Writing – original draft. W-xY: Software, Data curation, Writing – original draft, Formal analysis. HL: Formal analysis, Data curation, Software, Writing – original draft. XL: Visualization, Software, Writing – original draft, Methodology. W-cQ: Software, Methodology, Writing – original draft, Visualization. Z-wG: Writing – original draft, Software, Visualization, Methodology. JS: Resources, Validation, Project administration, Writing – review & editing, Funding acquisition, Supervision, Conceptualization.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesAvanciniABelluominiLTregnagoDTrestiniIMilellaMLanzaMExercise and Anemia in cancer patients: could it make the difference?Expert Rev Hematol. (2021) 14:979–85. 10.1080/17474086.2021.2007764SongZBLuSFengJFXuJMLiuYPLiuWEpidemiological investigation on the incidence and treatment status of cancer-related anemia in China.Chin J Oncol. (2019) 28:718–22.Chinese Society of Clinical Oncology Guidelines Working CommitteeChinese Society of Clinical Oncology (CSCO) Clinical Practice Guidelines for Cancer-Related Anemia 2022.Beijing: People’s Medical Publishing House (2022).ChenYLiYLZhouZPPuSM. Causes of cancer-related anemia.Chem J Life. (2021) 41:1747–53. 10.13488/j.smhx.20210092DangZLiuXWangXLiMJiangYWangXComparative effectiveness and safety of traditional Chinese medicine supporting Qi and enriching blood for cancer related anemia in patients not receiving chemoradiotherapy: a meta-analysis and systematic review.Drug Des Devel Ther. (2018) 13:221–30. 10.2147/DDDT.S181182HuangMNJiaYJChenJLiXJLinLS. Meta-analysis of the efficacy of traditional Chinese medicine in the treatment of cancer-related anemia.Chin J Integr Trad Western Med Surg. (2017) 23:343–8.CongSD. The impact of modified Chinese herbal medicine Danggui Buxue Decoction on the prognosis of patients with chemotherapy-induced anemia caused by tumors.Inner Mongol J Trad Chin Med. (2025) 44:40–2. 10.16040/j.cnki.cn15-1101.2025.08.026FengJLWuDPHeB. Efficacy of Shenqi Yangxue granules in treating tumor-related anemia and its impact on immune function.Liaon J Trad Chin Med. (2024) 51:91–4. 10.13192/j.issn.1000-1719.2024.04.025FuYYunQZhangY. Clinical study of Fuzhen Paste in the treatment of EPO-resistant cancer-related anemia.Henan J Trad Chin Med. (2016) 36:2140–2. 10.16367/j.issn.1003-5028.2016.12.0852HeLXuJSunLEZhuGQLuoSWangJ. Study on the clinical effect of integrated traditional Chinese and Western medicine in the treatment of cancer-related anemia.J Reflexol Rehabil Med. (2022) 3:8–10.HuangZHWuYXFeiF. Comparative clinical study of modified Danggui Buxue Decoction and conventional Western medicine in the treatment of cancer-related anemia.J Clin Exp Med. (2017) 16:787–90.LiSP.Clinical Study of Modified Guipi Decoction in the Treatment of Cancer-related Anemia in Gastric Cancer Patients.dissertation, Hefei: Anhui University of Chinese Medicine (2020).LiYJinFY. Observation on the efficacy of Jianpi Shengxue Granules in the treatment of chemotherapy-related anemia.World J Trad Chin Med. (2021) 16: 3557–60.LiCY. Efficacy of Buqi Shengxue Decoction combined with erythropoietin in the treatment of cancer-related anemia (Qi and Blood Deficiency Syndrome) and its impact on patient quality of life.Inner Mongol J Trad Chin Med. (2022) 41:59–61. 10.16040/j.cnki.cn15-1101.2022.07.017LiuYYZhangPTDengWQWangBQPengXXEffect of modified Danggui Buxue Decoction on the prognosis of patients with chemotherapy-induced anemia.J Oncol Pharm. (2020) 10:87–92.LiuLSWangSQ. Clinical study and safety evaluation of Danggui Buxue Decoction in the treatment of tumor-related anemia (spleen-kidney deficiency type).Chin J Trad Chin Med. (2024) 42:96–9. 10.13193/j.issn.1673-7717.2024.01.019LiuS.Clinical Study on Treating Anemia of qi Deficiency and Blood Stasis Type After Chemotherapy for Malignant Tumors Based on the Method of Gradual Replenishment of deficiency.dissertation, China: Yunnan University of Chinese Medicine (2024). 10.27460/d.cnki.gyzyc.2024.000529LuCLiuKFZengXLWenZQShuYCMoXYStudy on the effect of Bushen Jianpi Huayu therapy in enhancing the efficacy of rHuEPO for anemia after cancer chemotherapy.J Adv Modern Biomed. (2007) 7:1853–5. 10.13241/j.cnki.pmb.2007.12.028MaJJ.Therapeutic Effect of Jianpi Bushen Formula on Non-small Cell Lung Cancer-related Anemia.dissertation, Fuzhou: Fujian University of Traditional Chinese Medicine (2009).NiuR. Observation on the clinical efficacy of Xuesuzheng Granules in the treatment of cancer-related anemia.J Med Theory Pract. (2019) 32: 953–5. 10.19381/j.issn.1001-7585.2019.07.007QiJWangLX. Analysis of the clinical efficacy of 48 cases of integrated traditional Chinese and Western medicine in the treatment of post-chemotherapy anemia.World Latest Med Inform Abstracts J. (2015) 15:3.RenXWBieLY. Observation on the clinical efficacy of integrated traditional Chinese and Western medicine in the treatment of cancer-related anemia.J Basic Clin Oncol. (2019) 32:426–8.SongEFWuZHMeiSSZhangCDXiangQPeiXJClinical observation of Jianpi Shengxue Granules in the treatment of chemotherapy-related anemia in cancer patients.World J Trad Chin Med. (2017) 12:1534–7.TaoJ.Clinical Observation of Shenbai Fuzheng Granules in Treating Tumor-Related Anemia of Spleen-Kidney Deficiency Type Based on the Theory of Strengthening the Spleen and Tonifying the Kidney.dissertation, China: Southwest Medical University (2024).WangXBLiK. Observation on the clinical efficacy of Bushen Jianpi Shengxue Formula in the treatment of cancer-related anemia.J Liaon Univ Trad Chin Med. (2015) 17:164–7. 10.13194/j.issn.1673-842x.2015.02.061WangYMZhengXMLiuYHuDJXiaoHYGuoZJ. Effects of Yisui Bushen Formula on related anemia and immune function in patients with malignant lymphoma undergoing chemotherapy.Chin J Exp Formulae. (2017) 23:180–5. 10.13422/j.cnki.syfjx.2017190180WangRJLiSDWangPCuiYXYangQQWuY. Clinical study of modified Shengyu Decoction in improving moderate chemotherapy-related anemia in patients with advanced colon cancer.J Trad Chin Med Guide. (2021) 27:49–52. 10.13862/j.cnki.cn43-1446/r.2021.02.012WangJL. Clinical investigation of Buqi Shengxue Decoction in the treatment of chemotherapy-related anemia (Qi and Blood Deficiency Syndrome) in cancer patients.Chin J Health Preservat Care. (2021) 39:26–8.WenLBLiJALiuZY. Clinical observation of Guipi Decoction in the treatment of cancer-related anemia with Qi and Blood Deficiency Syndrome.Bright J Trad Chin Med. (2023) 38:3137–9.YaoJH.Clinical Study of Shengxue Pill Combined with EPO in the Treatment of Cancer-Related Anemia (Spleen and Kidney Deficiency Syndrome).dissertation, Lanzhou: Gansu University of Chinese Medicine (2021).ZengP.Clinical Study of Jianpi Yishen Formula in the Treatment of Advanced Non-small Cell Lung Cancer-related Anemia.dissertation, Wuhan: Hubei University of Chinese Medicine (2017).ZhaoY.Clinical Study of Shenrong Husui Formula in the Treatment of Cancer-Related Anemia (Qi and Blood Deficiency Syndrome).dissertation, Changsha: Hunan University of Chinese Medicine (2021).HuPLiaoDZ. Treatment of 30 cases of Cancer-related anemia with Yixue Shengshui Formula.Hunan J Trad Chin Med. (2021) 37:48–51. 10.16808/j.cnki.issn1003-7705.2021.09.015YuLLuoMHuYWangS. Observation on the efficacy of Huoxue Huayu Yangyin Formula combined with erythropoietin in the treatment of cancer-related anemia.J Chengdu Univ Trad Chin Med. (2018) 41:40–3. 10.13593/j.cnki.51-1501/r.2018.04.040ChenGF.Clinical Study of Yixue Formula in the Treatment of Cancer-Related Anemia.dissertation, Jinan: Shandong University of Traditional Chinese Medicine (2011).BaiYC.Clinical Study of Bazhen Decoction Combined with EPO in the Treatment of Cancer-related Anemia.dissertation, Tangshan: North China University of Science and Technology (2019).LuHJ.Clinical Observation of Jianpi Yishen Buqi Yangxue Therapy in the Treatment of Blood Deficiency Type Cancer-related Anemia in Patients with Advanced NSCLC.dissertation, Haerbin: Heilongjiang University of Chinese Medicine (2009).CaoYLiHYChenXYWangQZhangRRZhouCY. Clinical observation of Yiqi Yangxue Ointment combined with erythropoietin in the treatment of tumor-related anemia.Shanxi J Trad Chin Med. (2024) 40:28–30. 10.20002/j.issn.1000-7156.2024.10.011ChenJTWuDChenLGongP. Efficacy and safety evaluation of modified Danggui Buxue decoction in treating chemotherapy-induced anemia in cancer patients.J Pract Hosp Clin Med. (2025) 22:156–60.HuBJiangL. Observation on the efficacy of Jianpi Bushen Jiedu Formula in the treatment of cancer-related anemia.Yunnan J Trad Chin Med Chin Materia Med. (2017) 38:53–5. 10.16254/j.cnki.53-1120/r.2017.08.022HuangXF. Clinical observation of integrated traditional Chinese and Western medicine in the treatment of cancer-related anemia.Asia-Pacific J Trad Med. (2015) 11:109–10.HuangJJZhouYHYinDF. Clinical study of Ejiao (Donkey-hide Gelatin) in the treatment of cancer-related anemia in cancer patients.Asia-Pacific J Trad Med. (2018) 14:167–9.LiZW. Clinical observation of Bushen Yisui therapy in the treatment of 40 cases of cancer-related anemia.Hunan J Trad Chin Med. (2012) 28:43–4.LiY. Effects of integrated traditional Chinese and Western medicine treatment on changes in Hb, WBC, SF, and PLT values in patients with cancer-related anemia.Chin J Modern Pharmaceut Appl. (2016) 10:183–4. 10.14164/j.cnki.cn11-5581/r.2016.04.139LiQYYangWXLuYLinDMuHWangQEffectiveness of Shuanghuang Yangxue Decoction for treating Cancer-related Anemia with serum iron deficiency in Lung Cancer Patients: a randomized clinical trial.Integr Cancer Ther. (2025) 24:15347354251396042. 10.1177/15347354251396042LiangJ. Clinical observation and analysis of integrated traditional Chinese and Western medicine in the treatment of cancer-related anemia.J Modern Diag Treatment. (2017) 28:3555–6.LiuYYXieXDQuSX. Clinical observation of Zini Qizhen Decoction in the treatment of cancer-related anemia.Shenzhen J Integr Trad Chin Western Med. (2006) 16:310–2. 10.16458/j.cnki.1007-0893.2006.05.014LouYMaLZangLBZengYL. Observation on the efficacy of Buxue Yangrong Paste in the treatment of mild to moderate cancer-related anemia.J Clin Pract Trad Chin Med. (2020) 32:114–7. 10.16448/j.cjtcm.2020.0129MaJJ. Clinical observation of Yisui Granules in the treatment of chemotherapy-related anemia.Shanxi J Trad Chin Med. (2016) 32:13–5.PengTOuyangYLLiZDZhuWWZuoFSunJMClinical observation of Guipi Decoction in the treatment of mild to moderate gastric cancer-related anemia.New J Trad Chin Med. (2018) 50:178–80. 10.13457/j.cnki.jncm.2018.12.053QiaoXYYangSMCaiJS. Clinical observation of Shengyu Decoction in the treatment of anemia after chemotherapy for malignant tumors.Bright J Trad Chin Med. (2010) 25:1423–4.SheZCJiangYTangWHXuYQ. Clinical observation of Yiqi Huoxue therapy in the treatment of mid-late stage colorectal cancer-related anemia.Shanxi J Trad Chin Med. (2015) 31:16–8. 10.20002/j.issn.1000-7156.2015.03.008SunCLYangBGZhangGMLiaoDZ. Clinical observation of modified Danggui Buxue Granules in the treatment of cancer-related anemia.World J Trad Chin Med. (2020) 15:2422–5.WangYC.Clinical Study of Yangxue Decoction combined with EPO in the Treatment of Chemotherapy-related Anemia in Cancer Patients.dissertation, Guangzhou: Guangzhou University of Chinese Medicine (2015).WangXBLiK. Observation on the clinical efficacy of modified Zini Shengxue Formula in the treatment of non-small cell lung cancer-related anemia.Chin J Trad Chin Med. (2017) 35:2401–3. 10.13193/j.issn.1673-7717.2017.09.055WangFL.Clinical Observation of Modified Guipi Decoction Combined with EPO in the Treatment of Cancer-Related Anemia (Qi and Blood Deficiency Type).dissertation, Nanjing: Nanjing University of Chinese Medicine (2020).WangY. Study on the clinical efficacy of the traditional Chinese medicine formula Shengyu Decoction in the treatment of anemia after chemotherapy for gynecological malignant tumors.J Smart Health. (2022) 8:97–9. 10.19335/j.cnki.2096-1219.2022.9.033XuFGLongX. Efficacy Observation of Jianpi Yangxue Gao in Improving Clinical TCM Syndromes in Patients with Tumor-Related Anemia.Sichuan J Trad Chin Med. (2024) 42:112–3.YuLN. Observation on the efficacy of Buxue Yangrong Paste in the treatment of mild to moderate cancer-related anemia.J Clin Res Trad Chin Med. (2022) 14: 105–8.ZhangCC. Clinical efficacy of the traditional Chinese medicine formula Shengyu Decoction in the treatment of anemia after chemotherapy for gynecological malignant tumors.Chin J Modern Pharmaceut Appl. (2017) 11: 95–6.ZhangYY.Clinical Observation of Ejiao Jianzhong Decoction in Improving Tumor-Related Anemia After Gastric Cancer Surgery.dissertation, China: Anhui University of Chinese Medicine (2025). 10.14164/j.cnki.cn11-5581/r.2017.15.052ZhouGHGuoYHuangJFZhangFL. Observation on the efficacy of erythropoietin combined with Jiansheng Shengxue Granules in the treatment of cancer-related anemia.J Zhejiang Univ Trad Chin Med. (2011) 35:883–4. 10.16466/j.issn1005-5509.2011.06.062WangLGYangLChenLYQiuXHHuangBCShengXReview of the research status of Danggui Buxue Decoction in the treatment of cancer-related anemia.Chin J Med Innov. (2022) 19:180–3.NemethE. Hepcidin biology and therapeutic applications.Exp Rev Hematol. (2010) 3:153–5. 10.1586/ehm.10.1LiuM.Systematic Review and Meta-Analysis: Design and Implementation Methods.Beijin: People’s Medical Publishing House (2011).ChengZWuJLChenJF. Clinical observation on the treatment of male neoplastic anemia with Yixuesheng Capsule combined with recombination human erythropoietin.Chin J Integrat Med. (2009) 15:63–5. 10.1007/s11655-009-0063-3LiZN.Observation on the Clinical Efficacy of Yishen Gukang Formula on Cancer-related Anemia.dissertation, Beijing: China Academy of Chinese Medical Sciences (2012).
Edited by: Moklesur Rahman Sarker, Mercer University, United States
Reviewed by: Safayet Jamil, Atish Dipankar University of Science and Technology, Bangladesh
Shihab Uddin Ahmad, Shanghai Jiao Tong University, China